NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1 | 70 | US, Europe | GDC-0199 (ABT-199), Obinutuzumab | Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd | Lymphocytic Leukemia, Chronic | 01/15 | 11/16 | | |